Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Current Leases (2021 - 2025)

Kezar Life Sciences' Current Leases history spans 5 years, with the latest figure at $3.3 million for Q3 2025.

  • For Q3 2025, Current Leases changed N/A year-over-year to $3.3 million; the TTM value through Sep 2025 reached $3.3 million, changed N/A, while the annual FY2024 figure was $3.5 million, 17.07% up from the prior year.
  • Current Leases for Q3 2025 was $3.3 million at Kezar Life Sciences, down from $3.8 million in the prior quarter.
  • Across five years, Current Leases topped out at $3.8 million in Q2 2025 and bottomed at $1.2 million in Q4 2021.
  • The 5-year median for Current Leases is $3.0 million (2023), against an average of $2.8 million.
  • The largest annual shift saw Current Leases skyrocketed 113.93% in 2022 before it increased 17.07% in 2024.
  • A 5-year view of Current Leases shows it stood at $1.2 million in 2021, then soared by 113.93% to $2.6 million in 2022, then rose by 17.43% to $3.0 million in 2023, then grew by 17.07% to $3.5 million in 2024, then decreased by 7.57% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Current Leases are $3.3 million (Q3 2025), $3.8 million (Q2 2025), and $3.7 million (Q1 2025).